| Title |
Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023 / |
| Authors |
Kissling, Esther ; Maurel, Marine ; Emborg, Hanne-Dorthe ; Whitaker, Heather ; McMenamin, Jim ; Howard, Jennifer ; Trebbien, Ramona ; Watson, Conall ; Findlay, Beth ; Pozo, Francisco ; Bolt Botnen, Amanda ; Harvey, Ciaran ; Rose, Angela |
| DOI |
10.2807/1560-7917.ES.2023.28.21.2300116 |
| Full Text |
|
| Is Part of |
Eurosurveillance.. Stockholm : European Centre for Disease Prevention and Control (ECDC). 2023, vol. 28, iss. 21, p. [1-16].. eISSN 1560-7917 |
| Keywords [eng] |
Europe ; influenza ; multicentre study ; test-negative design ; vaccine effectiveness |
| Abstract [eng] |
BackgroundBetween October 2022 and January 2023, influenza A(H1N1)pdm09, A(H3N2) and B/Victoria viruses circulated in Europe with different influenza (sub)types dominating in different areas.AimTo provide interim 2022/23 influenza vaccine effectiveness (VE) estimates from six European studies, covering 16 countries in primary care, emergency care and hospital inpatient settings.MethodsAll studies used the test-negative design, but with differences in other study characteristics, such as data sources, patient selection, case definitions and included age groups. Overall and influenza (sub)type-specific VE was estimated for each study using logistic regression adjusted for potential confounders.ResultsThere were 20,477 influenza cases recruited across the six studies, of which 16,589 (81%) were influenza A. Among all ages and settings, VE against influenza A ranged from 27 to 44%. Against A(H1N1)pdm09 (all ages and settings), VE point estimates ranged from 28% to 46%, higher among children (< 18 years) at 49-77%. Against A(H3N2), overall VE ranged from 2% to 44%, also higher among children (62-70%). Against influenza B/Victoria, overall and age-specific VE were ≥ 50% (87-95% among children < 18 years).ConclusionsInterim results from six European studies during the 2022/23 influenza season indicate a ≥ 27% and ≥ 50% reduction in disease occurrence among all-age influenza vaccine recipients for influenza A and B, respectively, with higher reductions among children. Genetic virus characterisation results and end-of-season VE estimates will contribute to greater understanding of differences in influenza (sub)type-specific results across studies. |
| Published |
Stockholm : European Centre for Disease Prevention and Control (ECDC) |
| Type |
Journal article |
| Language |
English |
| Publication date |
2023 |
| CC license |
|
